LAG3

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Retrieved on: 
星期四, 五月 9, 2024
Sale, TNF, Phase, DSM-IV codes, Patient, MUC4, CD47, Pacific Rim, CTLA4, LAG3, Research, Tumor microenvironment, Conference, Downregulation and upregulation, Disease, Exercise, Chemistry, SRC, Macrophage, BOCA, TIGIT, Treatment-resistant depression, Neuroinflammation, Neoplasm, Deficit spending, TME, Pharmaceutical industry

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
  • INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Financial Results for the First Quarter Ended March 31, 2024:
    Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.
  • Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Retrieved on: 
星期一, 四月 8, 2024
TNF, MUC4, Alpha globulin, Disease, Macrophage, CD47, LAG3, Breast cancer, TIGIT, Poster, ADCP, TNBC, Vaccine

Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).  INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).  The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.

Key Points: 
  • The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03.
  • The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate.
  • Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

Retrieved on: 
星期一, 十月 30, 2023
Neoplasm, PD-L1, Trastuzumab, AD, Therapy, TNF, Macrophage, CD47, Research, Poster, Society for Immunotherapy of Cancer, CD8, Mouse, LAG3, Disease, Breast cancer, ADCP, Microglia, Brain, Tumor microenvironment, Phagocytosis, Safety, DMD, Cancer, Remyelination, Instituto de Biología y Medicina Experimental, Society, TME, MS, Vaccine, Medical imaging, Immunotherapy

Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.

Key Points: 
  • INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).
  • The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP.
  • INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP.
  • INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression.

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

Retrieved on: 
星期二, 九月 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Monoclonal antibody, BGNE, Cancer, Quality of life, SSE, OX40, LAG3, Patient, Medicine, European, Entrepreneurship, PD-L1, Safety, Tislelizumab, Pharmaceutical industry, BeiGene, HPK1, Novartis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
  • “BeiGene will continue to work with Novartis on development, regulatory and manufacturing priorities.
  • BeiGene has agreed to provide Novartis with ongoing clinical supply of TEVIMBRA to support its clinical trials.
  • Under the agreement, Novartis was responsible for regulatory submissions and had the right to commercialize in these licensed countries following regulatory approval.

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Retrieved on: 
星期四, 四月 13, 2023
Injection, CD47, Biotechnology, CD19, HLA, Lymphoid leukemia, Neoplasm, Nature Communications, MHC, NSG, Cancer, Bone marrow, CAR, HIP, LAG3, Spleen, Patient, CD39, Engineering, TIGIT, Mouse, SANA, PD-1, Recurrence, IND, BLI, Safety, Vaccine

“These preclinical data highlight that our hypoimmune CAR T cells can evade immune detection, persist, and clear tumor cells both acutely and over time.

Key Points: 
  • “These preclinical data highlight that our hypoimmune CAR T cells can evade immune detection, persist, and clear tumor cells both acutely and over time.
  • HIP CAR T cell-treated mice rapidly cleared the tumor cells, demonstrating the persistence and effectiveness of the HIP CAR T cells even after three months.
  • The efficacy of HIP CAR T cells in clearing tumors was assessed in immunodeficient mice that received low, middle, and high doses of either HIP CAR T cells or unmodified allogeneic CAR T cells intravenously.
  • HIP CAR T cells and unmodified allogeneic CAR T cells similarly reduced bone marrow cancer burden.

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
星期一, 三月 27, 2023
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Haematopoiesis, Ministry of Health (Israel), EAP, University, ASH, Therapy, Integrin alpha-1, CD16, T&E, CD57, Neoplasm, Survival, NK, Toxicity, Tandem, Cell, IP, Rated R, LAMP1, TCT, Ministry, Incidence, Highbridge Capital Management, Center for International Blood and Marrow Transplant Research, LAG3, Patient, CD56, University of Minnesota Medical School, CD62L, PDUFA, Viral, Poster, FDA, Society, Safety, Cryptocurrency, Pharmaceutical industry, Dentistry, Vaccine, Security (finance), Transplant

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.
  • As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.
  • “Our mission is to bring potentially curative therapies to patients,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • Especially since our engineered NK cell therapy candidates, which are derived from healthy donors, have demonstrated encouraging pre-clinical data that differentiate them from other NK cell therapy approaches.

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
星期六, 二月 18, 2023
Research, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Toxicity, Therapy, Hope, University of Minnesota Medical School, CD62L, CD56, TCT, Safety, Phenotype, NK, Patient, Tandem, CD16, LAG3, Cell, Center for International Blood and Marrow Transplant Research, University, Lymph, Bone marrow, Integrin alpha-1, Knowledge, Society, Transplant, CD57, LAMP1, Spatial analysis, Non-Hodgkin lymphoma, Pharmaceutical industry, Medical imaging

The meetings took place February 15-19 virtually and in person in Orlando, Florida.

Key Points: 
  • The meetings took place February 15-19 virtually and in person in Orlando, Florida.
  • “The data presented at Tandem demonstrate Gamida Cell’s expertise in developing potent, potentially curative cell therapies for patients with hematologic malignancies,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.
  • “The translational data from our Phase 3 study of omidubicel, our lead product candidate, show faster, multi-faceted immune response – as quickly as seven days—in omidubicel-treated patients compared to standard cord blood.
  • Patients transplanted with standard cord blood showed no such correlations at Day 7 post-transplant, and only began to show correlations starting at 14 days post-transplant.

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Retrieved on: 
星期一, 十一月 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bispecific monoclonal antibody, Neoplasm, Investment, PK, Annual general meeting, TAAS, Fab, PD-L1, Eli Lilly and Company, Ligation, TME, LAG3, CDH, TAM, Cancer, Macrophage, Myelocyte, B cell, CD47, Tumor microenvironment, ADCP, LILRB2, Coronavirus Scientific Advisory Board (Turkey), Family, Mab, SITC, SIGLEC, Patient, Antibody, Fine chemical, Vaccine

Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.
  • Anti-SIRP mAb ES004 potently potentiates antibody dependent cellular phagocytosis (ADCP) activity of antibodies against tumor associated antigens (TAAs) in vitro and in vivo.
  • Elpiscience has identified a novel function of SIGLEC15 that SIGLEC15 can induce monocyte apoptosis and its inhibitory effect on T cell function is indirect.
  • To learn more about the studies, please visit Elpiscience official website https://www.elpiscience.com
    Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide.

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
星期五, 十月 21, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Eli Lilly and Company, LAG3, Investment, SITC, Patient, Annual general meeting, CDH, Cancer, Coronavirus Scientific Advisory Board (Turkey), Company, PD-L1, Poster, Fine chemical

Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12.
  • The posters will highlight studies on five innovative molecules including anti-SIRP monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRP bispecific macrophage engager ES019.
  • Title: ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models
    Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide.
  • The Company has a robust pipeline of globally innovative cancer immunotherapies covering wide range of oncology targets and multiple proprietary technologies to enable discovery including its Bispecific Macrophage Engager (BiME) antibody platform for solid tumors.

Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC

Retrieved on: 
星期四, 六月 16, 2022
Antibody, Fibrosis, Cancer, Cirrhosis, RECIST, PD-1, LAG3, Security (finance), Therapy, Safety, Tumor microenvironment, CEO, U.S. Securities and Exchange Commission, Pharmacokinetics, Private Securities Litigation Reform Act, NASDAQ, Roche, LOXL2, SEC, Metastasis, TYRO3, IPF, Patient, Ruxolitinib, Neoplasm, VEGF, Idiopathic pulmonary fibrosis, PD-L1, GLOBE, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Galecto Biotech, NSCLC

Clinical evidence from patients with NSCLC suggests that high levels of galectin-3 in tumors leads to resistance to treatment with checkpoint inhibitors.

Key Points: 
  • Clinical evidence from patients with NSCLC suggests that high levels of galectin-3 in tumors leads to resistance to treatment with checkpoint inhibitors.
  • In multiple pre-clinical models, including NSCLC, GB1211 has been shown to reduce tumor growth and metastasis and increase efficacy of checkpoint inhibition.
  • Starting in the first-line treatment of NSCLC opens the door for Galecto to pursue numerous oncology opportunities.
  • The Phase 2a trial of GB1211 in combination with Tecentriq will be a 1:1 randomized, double blind, placebo-controlled trial in patients with NSCLC in the first line setting.